Phase 1 Trial Shows High Efficacy for IASO206 CAR-T Therapy
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
What happened
IASO Biotechnology presented first-in-human Phase 1 clinical results for IASO206, a BCMA-targeted in vivo CAR-T cell therapy, at the 2026 International Myeloma Society Annual Meeting. Dr. Wenqiang Yan, affiliated with the Chinese Academy of Medical Sciences, presented the findings, which showed a 90% objective response rate and a 90% MRD negativity rate in the tested population. Both response rates reached 100% in the high-dose cohort.
From manilatimes.net
Why it matters
The results demonstrate high efficacy for a therapy that generates functional CAR-T cells directly in patients without requiring lymphodepleting chemotherapy. This success in treating relapsed/refractory multiple myeloma could influence investment and research priorities within the cell therapy market.
From manilatimes.net
Who's involved
- Wenqiang YanPresented the first-in-human Phase 1 clinical results for IASO206.
- Chinese Academy of Medical SciencesAffiliation of Dr. Wenqiang Yan, who presented the clinical trial results.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Chinese Academy of Medical SciencesSpeculative
The success of the therapy might increase investment in related biopharmaceutical research and development.
Keep exploring
The entities involved
-
Chinese Academy of Medical Sciences
science academy in China
Nothing else this week.
-
Wenqiang Yan
researcher (ORCID 0000-0002-2179-6023)
Nothing else this week.